Patients with new-onset alopecia areata are at increased 10-year risk of developing several immune-mediated inflammatory diseases, according to a study.

In late February 2026, Eli Lilly and Incyte reported that the EMA’s CHMP issued a positive opinion recommending Olumiant for adolescents aged 12 to under 18 with severe alopecia areata, based on Phase ...

The gap in shared decision-making was similarly notable. Clinicians rated their own effectiveness in involving patients at 80.8 out of 100, while patients rated clinician involvement at only 69.1.

Eli Lilly wins CHMP backing to expand Olumiant use in adolescents with severe alopecia areata, with the EU approval decision ...

A new study published in journal of Clinical Drug Investigation suggest that baricitinib may be an effective treatment for ...

Treatment with a JAK inhibitor should be standard of care for any patient with alopecia areata who desires it, even if their hair loss is less than 50%, according to a speaker at South Beach Symposium ...

Alopecia areata is an autoimmune disease in which the body attacks the hair follicles. If you’re one of the 6.8 million people in the U.S. with this condition, what should you avoid with alopecia ...

Olumiant is already approved in Europe for people 18 and older with severe alopecia areata. Indianapolis-based Eli Lilly in 2009 signed an agreement with Incyte, a Wilmington, Del., biopharmaceutical ...

When Keira was diagnosed with alopecia areata at just 2 years old, her mother, Leslie, felt lost and unsure where to turn for support. "It was so isolating and lonely," said Leslie. "I felt desperate ...

Jada Pinkett Smith has been open about her struggle with alopecia, which causes hair loss, ever since first sharing the diagnosis with fans on an episode of Red Table Talk in 2018. Later, in ...

Eli Lilly advances CRISPR collaboration with Scribe Therapeutics for neurological and neuromuscular disorders; European ...